CSPC will retain all rights to SYS6005 in the remaining global markets. ROR-1 is highly expressed in embryonic tissue, and a variety of hematological malignancies and solid tumors. ROR-1 expression is ...
Radiance Biopharma is heating up the ROR1 race. The U.S. biotech is paying (PDF) China’s CSPC Megalith Biopharmaceutical $15 million upfront for rights to an antibody-drug conjugate (ADC ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback